The same holds true for assaying the formation of DSBs by the neutral comet assay.
This was true when assaying IFN-γ responses by ex vivo peptide stimulation on cells from the lung (Fig. 6B), mediastinal lymph node (Fig. 6C), and spleen (Fig. 6D) to the GP33 LCMV immunodominant epitope engineered into the influenza virus neuraminidase [24] or to the H-2Db immunodominant influenza NP366 epitope.
Whether different positivity rates reported for various SARS-CoV assays (12 – 17, 17 ) reflect true differences in assay performance, or merely differences in specimen type or differences in sample preparation (13 ), will only become apparent after comparative quality control tests using identical samples in the various assays and laboratories.
This is true of any assay, however, and the multiplex qPCR assay described here has the advantage of possessing two signatures for each strain, thus reducing the risk that some strains will escape detection.
Although there are several tried-and-true toxicity assays, the search is always on for methods that can even better predict toxic effects.
Most importantly, a true content mixing assay was used.
Care must also be taken to distinguish between (true) target and assay promiscuity of active compounds and be aware of experimental situations where this might not be possible.
As such, LDA provides potential solutions to the long-standing challenge of effectively determining true differences in assay performance, whether comparing reaction formulation, instrumentation, or as is the case for this study, data processing models.
This is especially true for assays that require multiple sections (e.g., some RNA- or DNA-based assays require three 10-micron sections per assay).
The same is true for Alu assays, with high correlation between results from three different assays.
